caa a22 4500 445340614 CHVBK 20180317142811.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s00436-011-2401-9 doi (NATIONALLICENCE)springer-10.1007/s00436-011-2401-9 Efficacy of Procox® Oral Suspension for Dogs (0.1% Emodepside and 2% Toltrazuril) against Experimental Nematode ( Toxocara cati and Ancylostoma tubaeforme ) Infections in Cats [Elektronische Daten] [Gabriele Petry, Eva Kruedewagen, Thomas Bach, Nadine Gasda, Klemens Krieger] Two exploratory studies were performed to determine the optimum therapeutic dose of Procox® for the removal of experimental infection with mature adult Toxocara (T.) cati and Ancylostoma (A.) tubaeforme in kittens. Procox® is a new oral suspension containing a combination of the nematocidal and coccidiocidal active principles emodepside (0.1 %) and toltrazuril (2 %). In the first study, 18 eight-weeks-old kittens were inoculated with 450L3 larvae of T. cati. 56days after infection, the kittens were allocated to three treatment groups and were treated with 0.5mg emodepside/kg body weight (group 1), 0.25mg emodepside/kg body weight (group 2) and 0.1mg emodepside/kg body weight (group 3), respectively. In the second study, 10 eight-weeks-old kittens were inoculated with 350L3 larvae of A. tubaeforme. Four weeks after infection, the kittens were allocated to two treatment groups and were treated with 0.1mg emodepside/kg body weight (group 1) or 0.25mg emodepside/kg body weight (group 2). In both studies, all kittens received a reference treatment with Drontal® (230mg pyrantel embonate and 20mg praziquantel per tablet) at the recommended dose of one tablet/4kg body weight 5days after treatment with Procox®. Anthelmintic efficacy was calculated by reduction in worm numbers expelled with the faeces following treatment with Procox® as compared with faecal worm numbers after reference treatment with Drontal®, by thus avoiding necropsy of the animals. In the T. cati study, emodepside was at 99.9 %, 100 % and 96.5 % effective at a dosage of 0.5mg, 0.25mg and 0.1mg per kg body weight, respectively. Against A. tubaeforme emodepside was at 95.7 % and 100 % effective at a dosage of 0.1mg and 0.25mg per kg body weight. No adverse events were seen during either study. It can be concluded that Procox® is efficacious for the control of mature adult T. cati and A. tubaeforme infections in cats at a single-dose rate of 0.25mg emodepside/kg body weight. The Author(s), 2011 Petry Gabriele Bayer Animal Health GmbH, Leverkusen, Germany aut Kruedewagen Eva Bayer Animal Health GmbH, Leverkusen, Germany aut Bach Thomas Bayer Animal Health GmbH, Leverkusen, Germany aut Gasda Nadine Klifovet AG, Munich, Germany aut Krieger Klemens Bayer Animal Health GmbH, Leverkusen, Germany aut Parasitology Research Springer-Verlag 109(2011-08-01), 37-43 0932-0113 109<37 2011 109 436 https://doi.org/10.1007/s00436-011-2401-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00436-011-2401-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Petry Gabriele Bayer Animal Health GmbH, Leverkusen, Germany aut NATIONALLICENCE 700 1- Kruedewagen Eva Bayer Animal Health GmbH, Leverkusen, Germany aut NATIONALLICENCE 700 1- Bach Thomas Bayer Animal Health GmbH, Leverkusen, Germany aut NATIONALLICENCE 700 1- Gasda Nadine Klifovet AG, Munich, Germany aut NATIONALLICENCE 700 1- Krieger Klemens Bayer Animal Health GmbH, Leverkusen, Germany aut NATIONALLICENCE 773 0- Parasitology Research Springer-Verlag 109(2011-08-01), 37-43 0932-0113 109<37 2011 109 436 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer